Competitor Analysis: CD19-Targeted Therapeutics

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Publication ID:

LMP0416001

Publication Date:

April 29, 2016

Pages:

Publisher:

La Merie Publishing

Countries:

Global [1]

USD 350.00

Pharma & Healthcare [2]

Therapeutic [3]

Oncology [4]

Description:

Competitor Analysis: CD19-Targeted Therapeutics 鈥� 2016 Update

This Competitive Intelligence report about听CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents:

Competitor Analysis: CD19-Targeted Therapeutics 鈥� 2016 Update

1. CD19-Targeted Therapeutics:

Fc-Engineered CD19-Targeted Antibodies
CD19-Targeted Antibody-Drug Conjugates
CD19-Targeted Immunotoxin
Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies
Other CD19-Targeted Bispecific Monoclonal Antibodes
Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells
Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells

2. Corporate CD19-Targeted Therapy Pipelines

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂